Bausch + Lomb. This drugmaker is expected to post quarterly earnings of $1.05 per share in its upcoming report, which represents a year-over-year change of +1.9%. Revenues are expected to be $2.43 ...

The Switch has been an enormous success — it’s the third-best-selling console of all time, behind only the PlayStation 2 and Nintendo’s own DS handheld — which presents both a big ...

This compares to the stock's 2.8% loss over the past four weeks. Bausch + Lomb scored a strong price increase on investors’ optimism surrounding a Financial Times report stating that the company ...

Bausch + Lomb Corp. shares rose the most ever following a report that the eye-care company is considering selling itself to disentangle from its debt-laden parent company. The Financial Times reported ...

Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation from ...

Eyecare company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported The stock of eyecare company Bausch + Lomb Corp. was up 14%on ...

Bausch + Lomb, one of the world’s largest contact lens ... Bausch Health’s market value has dropped to just $2.2bn as fears over its solvency grow and the company has become embroiled in ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Here are all the latest rumors, plus plenty of carefully considered speculation, about the Nintendo Switch 2. Although the Nintendo Switch 2 has yet to be officially announced, Nintendo has ...

At the time, Bausch + Lomb had just acquired an eyedrop for dry eye disease called Xiidra, as well as other assets, from Novartis in a deal valued at $2.5 billion. Mazzo told Saunders, that Trukera’s ...